NervGen Pharma Corp. Reports 2023 Year-End Financial Results and Operational Updates include: • Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 • CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 • Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord. Press release here: https://lnkd.in/e6T8xajD
NervGen Pharma Corp.
Biotechnology Research
Vancouver, British Columbia 1,490 followers
Restoring Life's Potential by Creating Innovative Solutions for the Treatment of Nervous System Damage
About us
NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or disease. NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin. NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory. NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.
- Website
-
http://www.nervgen.com
External link for NervGen Pharma Corp.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Vancouver, British Columbia
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
Get directions
2955 Virtual Way
480
Vancouver, British Columbia V5M 4X6, CA
Employees at NervGen Pharma Corp.
Updates
-
NervGen Pharma Corp. announces we've made the 2024 TSX #Venture50 list! The ranking by TSX Venture 50 recognizes the top 50 fastest growing companies on #TSXV in the past year. NervGen's President & CEO, Mike Kelly, talks about the significance of this recognition and the company’s roadmap to promote nervous system repair and functional recovery in spinal cord injuries. News release at ⫸ https://lnkd.in/ekqmjUKE Maverix Private Equity Shirley Ryan AbilityLab TMX Group
-
NervGen Pharma Corp. reposted this
Daniel Mikol MD, PhD, Chief Medical Officer, NervGen Pharma Corp. (Source: NervGen Pharma press release, 2/15/24) https://lnkd.in/gWxU6yRS Shirley Ryan AbilityLab #spinalcordinjury #clinicaltrial
-
-
Daniel Mikol MD, PhD, Chief Medical Officer, NervGen Pharma Corp. (Source: NervGen Pharma press release, 2/15/24) https://lnkd.in/gWxU6yRS Shirley Ryan AbilityLab #spinalcordinjury #clinicaltrial
-
-
NervGen Pharma Corp. reposted this
NervGen Pharma Corp. on track to complete enrollment, deliver data readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury: https://lnkd.in/eGpRndkP
-
NervGen Pharma Corp. on track to complete enrollment, deliver data readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury: https://lnkd.in/eGpRndkP
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
newsfilecorp.com
-
A first-in-class therapeutic that has the potential to enable repair of the nervous system, our lead drug candidate, NVG-291, is currently being evaluated in a Phase 1b/2a clinical trial for individuals with spinal cord injury. Learn more about the development of NVG-291 in our full video: https://lnkd.in/eA7cnJ5f #innovation #clinicaltrials #spinalcordinjury
-
NervGen Pharma Corp. reposted this
In 2009, Dr. Jerry Silver began focusing on creating treatments that enhance the repair of the nervous system by preventing signals that inhibit the repair process. In 2015, NVG-291 was identified. Watch the full video: https://lnkd.in/eA7cnJ5f #spinalcordinjury
-
In 2009, Dr. Jerry Silver began focusing on creating treatments that enhance the repair of the nervous system by preventing signals that inhibit the repair process. In 2015, NVG-291 was identified. Watch the full video: https://lnkd.in/eA7cnJ5f #spinalcordinjury
-
Great interview with NervGen Pharma Corp. ‘s Nana Collett in Life Science Leader.
“I’m a big believer in open-source information as much as possible,” says Nana Collett, VP, program management at NervGen Pharma Corp. “I understand companies need proprietary information, but I’m a bit radical this way. I believe that as an ecosystem, we’re going to get stronger if we can find our way to more data sharing.” https://lnkd.in/eCtmVc7K 𝐒𝐨𝐮𝐫𝐜𝐞: Life Science Leader/Louis Garguilo #spinalcordinjury #biopharma
-